A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Keymed Biosciences Co.Ltd24 enrolled

Overview

This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atopic Dermatitis

Interventions

CM310BIOLOGICAL

CM310 600 mg + 300 mg, subcutaneous injection

Eligibility

Sex: ALLMin age: 12 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 12 years ≤ age ≤ 18 years * With atopic dermatis * Voluntarily sign the informed consent form Exclusion Criteria: * Weight \< 30 kg * Major surgery planed during the study

Locations (1)

Beijing Children's Hospital Capital Medical University

Beijing, China

Outcomes

Primary Outcomes

Adverse events

Incidence of adverse events.

Time frame: at week 14

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.